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Abstract
Background: SPC-c-Raf-1-BxB transgenic mice develop genetically induced disseminated lung adenocarcinoma
allowing examination of carcinogenesis and evaluation of novel treatment strategies. We report on assessment of
lung tumour growth kinetics using a semiautomated region growing segmentation algorithm.
Methods: 156 non contrast-enhanced respiratory gated micro-CT of the lungs were obtained in 12 SPC-raf
transgenic (n = 9) and normal (n = 3) mice at different time points. Region-growing segmentation of the aerated
lung areas was obtained as an inverse surrogate for tumour burden. Time course of segmentation volumes was
assessed to demonstrate the potential of the method for follow-up studies.
Results: Micro-CT allowed assessment of tumour growth kinetics and semiautomated region growing enabled
quantitative analysis. Significant changes of the segmented lung volumes over time could be shown (p = 0.009).
Significant group differences could be detected between transgenic and normal animals for time points 8 to 13
months (p = 0.043), when marked tumour progression occurred.
Conclusion: The presented region-growing segmentation algorithm allows in-vivo quantification of multifocal lung
adenocarcinoma in SPC-raf transgenic mice. This enables the assessment of tumour load and progress for the
study of carcinogenesis and the evaluation of novel treatment strategies.
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Background
A number of genetic animal models of lung cancer has
been developed to better understand the molecular
causes of this disease. In-vivo imaging in these disease
models can allow a better understanding of biological
processes and a time-course assessment of therapeutic
approaches. We here report on longitudinal in-vivo
micro-CT measurements of lung tumour in a transgenic
mouse model of lung cancer.
The animal model examined has been reported in the
literature already [1-5]. In the SPC-c-Raf-1-BB (referred to
as SPC-raf) transgenic mouse model overexpression of the
serine-threonine-kinase c-raf to alveolar epithelium is
achieved by use of the surfactant protein C (SPC) promo-
ter. Raf is an essential constituent of the mitogen activated
protein kinase (MAPK) signalling pathway, that has been
found to communicate a cell surface receptor signal to the
DNA in the nucleus [4]. This MAPK pathway is often
found to be dysregulated in human malignancies [3].
Essentially, the targeted overexpression in SPC-raf trans-
genic animals results in adenocarcinomas of the lung, with
multifocal adenomatous hyperplasia being defined as the
earliest proliferative lesion of dysplastic cells. Histopathol-
ogy of this animal model has been obtained at different
time-points to show the time course of the tumour pro-
gression. The first distinct morphological changes seen by
histopathology have been reported to occur by the age of
2 months. By the age of 8 month, approximately 60-70%
of the lungs have been reported to be tumour, as judged
by histopathology. At the age of 12 months advanced
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provided the original work is properly cited.tumour stage can be found macroscopically, affecting the
entire lung [3].
This animal model allows probing for mechanisms of
carcinogenesis based on a genetic cascade that also plays a
crucial role in the development of adenocarcinoma of the
lungs in humans. Furthermore, it offers the opportunity to
study carcinogenesis in a more realistic setting as com-
pared to models of implanted (xenograft) tumours into
immunodeficient mice. In fact, the animals are still immu-
nologically competent, while the continuous expression of
the transgene secures continuous tumour pressure. Thus,
the relevance of overexpressed protooncogenes or disabled
tumour suppressor genes can be studied.
Different imaging modalities have been reported and
their advantages and disadvantages have been evaluated
for imaging of murine lung pathology. Comparatively
fast assessment of morphology can be obtained using
micro-CT [6]. Furthermore, metabolic information on
the examined tissue can be provided by the use of other
modalities such as micro-positron emission tomography
(PET), magnetic resonance imaging (MRI) or optical
imaging [7-9]. Spatial correlation with morphological
information, e.g. by micro-PET/micro-CT registration,
allows precise localization of this information on meta-
bolism. More recently, molecular imaging of responsive-
ness to chemotherapy at the tumour site or imaging of
disease candidate genes has been reported.
In this study we report on the use of a micro-CT
quantification algorithm for the longitudinal assessment
of tumor progression in SPC-raf transgenic mice.
Methods
Animals
12 mice (SPC-raf transgenic n = 9 and wildtype n = 3)
were examined (Table 1). Transgenic mice were
maintained as hemizygotes in the C57 BL/6 mouse
strain background, polymerase chain reaction was used
to secure transgenic status. All experiments were per-
formed according to a protocol as approved by the local
regulatory authorities (No. 33-42502-06/1081, Lower
Saxony State Office for Consumer Protection and Food
Safety, Germany).
In-vivo micro-CT imaging was first performed at the
age of 2 months (day 55 to day 61) and repeated every 4
weeks. Follow-up examinations were repetitively carried
out until the animal had to be euthanized due to medi-
cal condition or termination of the study. The follow-up
had to be terminated on day 146 in one animal, in the
other animals between day 362 and 547. A total of 156
CT exams were carried out in this study.
Isoflurane inhalation anaesthesia was administered
using a nose cone. The animals were placed in prone
position on a multimodality bed that enables changes
between the different imaging modalities without reposi-
tioning. A pressure transducer pad was placed under the
animal’s chest for respiratory monitoring, which was
used for respiratory gating and for control of
anaesthesia.
Micro-CT
Non contrast-enhanced prospectively respiratory gated
micro-CT was performed (GE Explore Locus, General
Electric Healthcare, Chalfont St. Giles, UK) with an
effective pixel size of 0.094 mm (80 kV, 450 μA, 360
projections/scan, exposure time/projection 100 ms, scan
technique 200°, 4 × 4 detector bin mode). The scan
FOV was 32.8 mm. For respiratory gating the signal
from the transducer pad was used to generate the image
acquisition time points using the software Biovet (m2 m
Imaging, Newark, NJ, USA). Images of the chest were
Table 1 Animals examined in this study
Animal No. Genetical status Sex Follow-up (d) Thoracic organs (g) Body weight (g) Thoracic organs/body weight
1 SPC-raf F 399 1.49 23.03 0.05
2 SPC-raf F 362 1.22 18.70 0.07
3 SPC-raf M 536 1.44 36.95 0.04
4 SPC-raf F 466 1.34 23.63 0.06
5 SPC-raf F 466 1.02 17.90 0.06
6 SPC-raf F 466 0.95 17.78 0.05
7 SPC-raf M 547 1.44 28.77 0.05
8 SPC-raf M 546 1.15 29.93 0.04
9 wild-type M 547 0.49 50.20 0.01
10 wild-type M 546 0.45 47.00 0.01
11 wild-type M 398 - - -
12 SPC-raf F 146 - - -
Sex and age at last micro-CT are given. Note that female animals have shorter follow-up times (see discussion). In animals 11 and 12 no histology was obtained.
The ratio of thoracic organ weight and total body weight clearly shows the differences between transgenic and control animals at necropsy.
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Expected mean radiation dose was calculated to be 197
mGy based on phantom and cadaver measurements in a
previous study [10].
Histology
The imaging findings were correlated to necropsy and
histology in 10 cases (8 transgenic and 2 control, see
table1) by direct visual comparison. In two animals
no histology was obtained. At necropsy lung surface
was assessed for tumour affection and correlated to
imaging. After necropsy the excised lungs were filled
with Tissue-Tek O.C.T.
® (Sakura, Finetek Europe,
N L )a n ds u b s e q u e n t l yf i x e di n4 %b u f f e r e df o r m a l i n
(pH 7.2). After dehydration (Shandon Hypercenter,
XP) lungs were embedded in paraffin. Sections (2 μm
thick) were deparaffinized with xylene and H&E
stained.
Post-Processing
For quantification of the multifocal tumours a segmen-
tation of the aerated parts of the lungs was used as a
surrogate parameter, as direct measurement was not fea-
sible. A region-growing algorithm for micro-CT quanti-
fication of tumour load and progress for diffuse lung
adenocarcinoma was established and validated earlier
[11]. The open-source software MevisLab (Fraunhofer
Mevis, Bremen, Germany) was applied, 20-40 seed
points were used to generate the region growing seg-
mentation with a segmentation threshold tolerance of
2% (Figure 1 and 2). For each data set 3 separate seg-
mentations were performed and the results of the 3
measurements were averaged.
Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics 19 (IBM Corp., Armonk, NY, USA). A repeated
measurement analysis was performed. Due to the lim-
ited number of animals the number of time points ana-
lysed had to be reduced. Analysis was performed for
time points 2, 4, 6, 7-13 months. Due to a limited num-
ber of measurements one animal had to be excluded
from the statistical analysis (see above, the animal had
to be euthanized on day 146). Furthermore a linear
regression analysis was performed and the correlation
coefficient was calculated. P < 0.05 was considered as
statistical significant.
Results
Micro-CT and Post-Processing
No adverse events occurred due to the imaging proce-
dures or anesthesia. Image quality was good in most
cases and acceptable in all cases.
In this follow-up study progressive tumour burden
could be seen in SPC-raf transgenic mice, while no
obvious changes were noted in the control group (Fig-
ure 3 and 4). Visual correlation of histology and micro-
CT at the corresponding time-point showed good
accordance.
The region growing segmentation using the described
post-processing algorithm could be performed in all
cases. In the evaluation study repositioning of seed
points due to overspilling of the segmentation volume
into adjacent structures was not necessary using the
same algorithm for 90 segmentations [11], in this study
in repositioning was necessary in about 10 cases out of
468 segmentations. This necessitated reevaluation of the
Figure 1 Segmentation of aerated lung volume as a surrogate parameter to assess the multifocal tumor spread. Here in control animal
no intrapulmonary masses are seen in micro-CT imaging (A). Seed points are placed manually in the aerated lung (B). Segmentation of the
aerated lung is performed by applying a region growing algorithm (C). The entire aerated parts of the lung are segmented. No spread of
segmentation volume into adjacent structures occurred.
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into aerated parts of the lungs. This way tumour burden
and growth was assessed quantitatively using the
decrease in aerated lung volume as a surrogate. The
initial increase in lung volume in the first 4 months was
attributed to normal growth.
In the comparatively small group examined here,
tumour growth seemed to occur at a later point of time
Figure 2 Segmentation of aerated lung volume as a surrogate to assess the multifocal tumor spread in SPC-raf transgenic animal.
Micro-CT showing the distinctive diffuse bilateral tumour growth (A). Seed points are placed manually in the aerated lung (B). Segmentation of
the aerated lung is performed applying a region growing algorithm (C). Note that the lung areas consolidated by tumour are correctly excluded
from the segmentation volume, no overspilling of segmentation volume into adjacent anatomical structures.
Figure 3 Time-course of tumour progressing in micro-CT of a single SPC-raf transgenic animal (No.2; months 2-13).A x i a ls l i c e
orientation in corresponding positions. The multifocal tumour progression is clearly depicted. Histology at 13 months shows distinctive tumour
burden in corresponding areas.
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animals showed clinical signs of tumour necessitating
sacrifice earlier compared to male animals.
Statistical analysis
Repeated measurement analysis of the time points 2, 4,
6, 7-13 months showed significant changes of the seg-
mented lung volumes over time (p =0 . 0 0 9 ) .I n t e r a c t i o n
of the measurements was rejected (p =0 . 0 3 5 ) .T e s t i n g
for group differences did not show significant results,
due to the small number of animals and the spread of
lung volume at early time points in normal animals.
Analysis of time points 8 to 13 months, when tumour
progression occurs, showed significant group differences
(p = 0.043). Linear regression analysis yielded equation
1 to calculate lung volume. The correlation coefficient
was determined as R = 0.538.
Vollung = −0.01 × (month − 1) + 0.315 ml (1)
Discussion
In this study we examined the tumour growth kinetics
of SPC-raf transgenic mice by serial micro-CT examina-
tions. Small animal imaging allows assessment using
each animal as its own control in follow-up examina-
tions. Given the relevant inter-individual spread it has
the potential to optimize studies. To prevent intra-indi-
vidual spread sophisticated imaging and post-processing
techniques have to be established as elaborated below.
An advantage of imaging especially in diffuse or multifo-
cal pathologies is that the entire volume can be assessed
additional to circumscribed areas of sectional histo-
pathology obtained.
Very few studies on follow-up micro-CT examination
have been performed in transgenic murine models of
lung cancer (mainly K-ras transgenic) [12-14]. Other
groups performed follow-up examination in single
lesions caused by intrapulmonary injection of tumour
cells or several/multiple lesions initiated by intraperito-
neal injection of urethane [15-17]. To the best of our
knowledge, no report on micro-CT assessment of
tumour growth kinetics in the SPC-raf transgenic lung
tumour mouse model has been published so far.
Furthermore, the follow-up exams reported did usually
include only a limited number of imaging time points as
compared to up to 15 time points in this study, allowing
a more detailed assessment of growth kinetics. Further
studies have shown the use of micro-CT for the detec-
tion of primary lung tumours or pulmonary metastases
without a follow-up being performed [7,18].
All the various imaging approaches of murine animal
models of human lung tumour have different advantages
and disadvantages. Some animal models are highly artifi-
cial with regard to the mechanism of carcinogenesis or
the immunological competence of the tumour bearing
organism. But they may provide imaging characteristics
similar to the situation in humans with a single com-
paratively well-defined lesion. The multifocal tumour
growth in the SPC-raf transgenic animal model exam-
ined in this study limits direct application of established
radiological imaging techniques in humans. However, it
has already been reported that this animal model allows
examination of the potential relevance of human proto-
o n c o g e n e so rd i s a b l e dt u m o u rs u p p r e s s o rg e n e si na n
immunologically competent environment. Thus, aspects
of human carcinogenesis may be better understood
highlighting the clinically translational aspects of the
research.
In the animals examined in this study tumour growth
seemed to occur at a later point of time in male animals
as compared to female animals, furthermore females
showed clinical signs of tumour necessitating to sacrifice
the animals earlier compared to male animals (Table1).
This has not been reported for the SPC-raf transgenic
animal model, yet. However, due to the genetic mechan-
ism of tumour induction in this model it might repre-
sent a relevant finding to understand lung tumour
carcinogenesis. Further experiments have to be per-
formed in order to validate the potential finding and
present a hypothesis for the origin. The primary focus
of this study was to demonstrate the use of micro-CT
for assessment of tumour load and growth. The issue
demonstrates the potential additional benefit of the
Figure 4 Estimated marginal means of the segmentation
volumes of the aerated parts of the lungs as an inverse
surrogate parameter for tumour burden in SPC-raf transgenic
(blue) and control animals (green) against time. Initial increase is
assumed to result from normal growth of the animals. Note the
distinct separation of the curves from 5 months on. Statistical
analysis of later timepoints showed significant differences (p =
0.043).
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esis applying intraindividual time-course assessment.
Micro-CT imaging applying the setup described above
did not result in adverse events, even though animals
had advanced tumour stages at the later time points. In
synopsis with other studies performed we attribute this
to the use of isoflurane inhalation anaesthesia, respira-
tory monitoring and the use of a heating blanket. We
performed prospective respiratory gating as it has been
reported to significantly increase image quality. How-
ever, more sophisticated gating techniques such as ret-
rospective or intrinsic gating or high-speed single-breath
hold techniques could further optimize imaging [19-22].
MRI has been reported to allow high spatial resolution
imaging of the lung. Martiniova et al. even reported bet-
ter detection of small lesions with MRI as compared to
micro-CT [7]. Optical imaging techniques or micro-PET
enable assessment of functional parameters but have
limitations in high resolution imaging of morphology
[8,23]. Various post-processing strategies have been
reported allowing precise evaluation of specific aspects
of the image data.
Dose measurements for the applied micro-CT proto-
col were performed in a phantom and ex-vivo in pre-
vious studies. The effective dose calculated from these
measurements was 154 mGy for the selected protocol.
An additional radiation dose has to be added for plan-
ning the scan-area under fluoroscopy. For this a dose
of 19 mGy/min was measured, resulting in 202 mGy/
scan [11]. Animals received between 4 and 15 repeti-
tive exams with 4 weeks interscan interval (MV = 13.0,
SD = 3.05). The calculated accumulative dose ranged
from 808 mGy within 91 days (4 exams) to 3030 mGy
within 475 d (15 exams). The mean calculated accu-
mulative dose was 2626 mGy within approximately 450
d. These dose values in synopsis with a reported LD50/
30 (dose that is lethal in 50% of the animals within 30
days) of 7.52 Gy demonstrate the relevance of the
issue [24]. However, we consider direct adverse effects
(structural changes to the lungs or unintended radia-
tion effects on the tumour growth) to be unlikely.
Although gene expression changes have been seen in
cell cultures with doses as low as 20-500 mGy [25]
structural changes like fibrosis were not even seen fol-
lowing doses as high as 7-9 Gy [24] and the reported
values for therapeutic radiation also amounted to
values as high as 15.5 Gy [12].
In conclusion the presented region-growing segmenta-
tion algorithm allows longitudinal in-vivo quantification
of multifocal lung adenocarcinoma in SPC-raf transgenic
mice. This enables the assessment of tumor load and
growth kinetics for the study of carcinogenesis and the
evaluation of novel treatment strategies.
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